Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Sponsor: Tempest Therapeutics
This PHASE1 trial investigates Colorectal Cancer and Endometrial Cancer and is currently completed. Tempest Therapeutics leads this study, which shows 3 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
3 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Nov 2024 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
First recorded
May 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tempest Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ann Arbor, United States , Aurora, United States , Baltimore, United States , Grand Rapids, United States , Huntersville, United States , Nashville, United States , Oklahoma City, United States , Philadelphia, United States , Pittsburgh, United States , San Antonio, United States and 1 more location